Analyst Josh Jennings from TD Cowen maintained a Buy rating on Establishment Labs Holdings and keeping the price target at $60.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Josh Jennings has given his Buy rating due to a combination of factors that suggest strong future performance for Establishment Labs Holdings. The anticipated positive update from the company’s second-quarter results is a significant factor, with the US Motiva revenue already preannounced to be between $9.5 million and $10 million, which exceeds previous estimates. This indicates a successful ramp-up of the US Motiva launch, contributing to the company’s growth prospects.
Additionally, the global revenue estimate of $51 million, which includes modest growth from international markets, appears achievable. The company only needs to generate around $41 million in international sales to meet this target, a figure that seems attainable given the stable to improving international market trends and the recent launch of Preserve. Jennings also notes that the company’s 2025 revenue growth guidance supports expectations for continued growth, further justifying the Buy rating.
According to TipRanks, Jennings is a 3-star analyst with an average return of 0.8% and a 47.48% success rate. Jennings covers the Healthcare sector, focusing on stocks such as TransMedics Group, Boston Scientific, and Abbott Laboratories.